Ying-Ren Zhao1, Ling Gong, Ying-Li He, Fang Liu, Chang Lu. 1. Department of Infectious Diseases, First Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. zhaoyingren@sohu.com
Abstract
AIM: To investigate the relationship between the polymorphism of class II transactivator (CIITA) gene promoters and chronic hepatitis B (CHB). METHODS: Genomic DNA was prepared from peripheral blood leukocytes. Promoters I, III and IV of gene were analyzed respectively with polymerase chain reaction single strand conformation polymorphism (PCR-SSCP) in 65 patients with CHB, 26 patients with acute hepatitis B (AHB) and 85 normal controls. RESULTS: No abnormal migration was found in PCR-SSCP analysis of the three promoters in the three groups. Also, no sequential difference was observed at the three promoters among the CHB patients, AHB patients and normal controls. CONCLUSION: No polymorphism in promoters I, III and IV of CIITA gene exists in CHB patients, ABH patients and normal controls, suggesting that the promoter of CIITA gene might be a conserved domain.
AIM: To investigate the relationship between the polymorphism of class II transactivator (CIITA) gene promoters and chronic hepatitis B (CHB). METHODS: Genomic DNA was prepared from peripheral blood leukocytes. Promoters I, III and IV of gene were analyzed respectively with polymerase chain reaction single strand conformation polymorphism (PCR-SSCP) in 65 patients with CHB, 26 patients with acute hepatitis B (AHB) and 85 normal controls. RESULTS: No abnormal migration was found in PCR-SSCP analysis of the three promoters in the three groups. Also, no sequential difference was observed at the three promoters among the CHB patients, AHB patients and normal controls. CONCLUSION: No polymorphism in promoters I, III and IV of CIITA gene exists in CHB patients, ABH patients and normal controls, suggesting that the promoter of CIITA gene might be a conserved domain.
Authors: S Sartoris; A Brendolan; A Degola; M G Testi; R Chignola; A Scarpa; M Scardoni; G Contreas; L Pinelli; C Lunardi; R Beri; C Pera; G B Ferrara; A P Riviera; G Tridente; G Andrighetto Journal: Hum Immunol Date: 2000-06 Impact factor: 2.850
Authors: S Sartoris; M T Valle; A L Barbaro; G Tosi; T Cestari; A D'Agostino; A M Megiovanni; F Manca; R S Accolla Journal: J Immunol Date: 1998-07-15 Impact factor: 5.422
Authors: Peter J van den Elsen; Tjadine M Holling; Hedwich F Kuipers; Nienke van der Stoep Journal: Curr Opin Immunol Date: 2004-02 Impact factor: 7.486